Mitochondria are cellular organelles that orchestrate a vast range of biological processes, from energy production and metabolism to cell death and inflammation. Despite this seemingly symbiotic relationship, mitochondria harbour within them a potent agonist of innate immunity: their own genome. Release of mitochondrial DNA into the cytoplasm and out into the extracellular milieu activates a plethora of different pattern recognition receptors and innate immune responses, including cGAS-STING, TLR9 and inflammasome formation leading to, among others, robust type I interferon responses. In this Review, we discuss how mtDNA can be released from the mitochondria, the various inflammatory pathways triggered by mtDNA release and its myriad biological consequences for health and disease.
Introduction
Serving as a first line of defence, the innate immune system guards us against a plethora of insults and invading microorganisms. Infection by pathogenic agents is detected in cells by pattern recognition receptors (PRRs) which recognise specific pathogen-associated molecular patterns (PAMPs). PRRs can be broadly classified into four distinct groups: NOD-like receptors (NLRs), Toll-like receptors (TLRs), retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) and C-type lectin receptors (CLRs) [1] . Upon detection of a PAMP, PRRs initiate a multitude of different signalling pathways, which culminate in the up-regulation of various type I interferons, pro-inflammatory chemokines and cytokines. These prime the adaptive immune system and create a hostile environment for the microorganism in which to survive. Additionally, damage-associated molecular patterns (DAMPs) are immune triggers that arise from the cell itself, such as proteins or DNA, and can activate innate immune pathways [2] .
Mitochondria first appeared in eukaryotic cells about two billion years ago as a-proteobacterium, in what is thought to be an endosymbiotic relationship [3, 4] . Over time, these bacteria evolved to become the much-studied organelle that we know today, playing crucial roles in metabolism, calcium homeostasis and cell death. Nevertheless, they have maintained an independent genome, which encodes 37 genes, comprised of 13 mRNAs forming key components of the oxidative phosphorylation system, in addition to 2 ribosomal RNA components and 22 tRNAs [3, 4] . An estimated 1,000 proteins are located in the mitochondria, all of which, except those encoded by mtDNA, are translated in the cytosol and imported into the mitochondria [5] .
Mitochondrial DNA itself is a circular molecule of doublestranded (ds)DNA. Transcription of both the heavy and light strand results in long, full-length transcripts which are processed by RNase enzymes to produce mature mRNA, tRNA and ribosomal RNA. In mammals, the polymerase responsible for mtDNA replication is DNA polymerase c, but as POLc cannot replicate dsDNA, the DNA helicase Twinkle is required to act directly before to unwind the DNA structure. Newly synthesised single-stranded (ss)DNA is bound by mitochondrial single-stranded DNA-binding protein to prevent secondary structure formation and attack by nucleases. Mitochondrial DNA replication has recently been reviewed extensively elsewhere [6] ; here, we focus on the unique aspects of mtDNA which make it immunostimulatory. We will then discuss how mtDNA which is ejected from the mitochondria under specific circumstances can activate different innate immune pathways, including cGAS-STING signalling, inflammasomes and Toll-like receptors. We will also focus on the role of mtDNA in the formation of neutrophil extracellular traps (NETs) and the transfer of mtDNA between cells.
Mitochondrial DNA as a stimulator of the immune system
Potentially stemming from its bacterial origin, mitochondrial DNA is sensed as "foreign", suggesting that it is seen differently to "self" DNA in cells. One example of this can be seen in its methylation status, where many studies have reported mtDNA to be hypomethylated compared to nuclear DNA [7, 8] , despite the presence of DNA methyltransferases in the mitochondria [9, 10] . Some groups have reported aberrant methylation patterns of mtDNA, including 5methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) at CpG motifs [9] [10] [11] [12] [13] [14] , although others have proposed technical limitations to this work and using more sensitive techniques report that mtDNA is devoid of CpG methylation [15] . Clearly, more effort is required in determining the precise degree of methylation in mtDNA, but if studies showing an absence of CpG methylation are correct, then mtDNA would harbour unmethylated CpG motifs similar to bacterial DNA, which could potentially activate pattern recognition receptors such as TLR9, absent in melanoma 2 (AIM2) and cGAS [15] [16] [17] [18] . Mitochondrial DNA replication and transcription itself may represent a rich source of potential activators of DNA pattern recognition receptors; for example, RNA:DNA hybrids form during transcription, in addition to long stretches of ssDNA and R-loops composed of RNA:DNA hybrids with a non-template ssDNA which can be recognised by cGAS [16] .
Mitochondrial DNA exists in the mitochondrial matrix in close proximity to the electron transport chain, a major source of reactive oxygen species. Due to this, it is particularly vulnerable to oxidation, resulting in mtDNA mutations which can contribute to the pathogenesis of cancer [17] , diabetes [18] and ageing [19] . It was thought the cell had limited capacity to repair mtDNA; however, multiple repair pathways are now well characterised [20] . Mitochondrial DNA is often schematically represented as a plasmid structure; however, this is an over-simplification. Rather, super-resolution imaging has revealed that it is densely compacted into nucleoids consisting of one copy of mtDNA and a number of different proteins [21] , the most notable of which is mitochondrial transcription factor A (mtTFA, commonly referred to as TFAM). It might be assumed that the compaction of mtDNA into protein structures shields DNA from recognition, but this is not the case as we shall discuss further in this Review, and in fact, a number of studies have shown that TFAM itself might be immunostimulatory [13, 14] .
In a landmark study in 2004, Collins et al [22] found that injecting mtDNA into the joints of mice resulted in localised inflammation and arthritis. Further investigation revealed that the inflammation was dependent on the presence of oxidatively damaged bases in the mtDNA, as injection of an oligodeoxynucleotide (ODN) with the same sequence but without the oxidised residue had no effect. The observation that mtDNA can elicit potent immune responses opened a whole new field of research, and it is now appreciated that mtDNA can stimulate many PRRs, including cGAS, TLR9 and inflammasomes ( Fig 1) . Release of mtDNA from mitochondria and subsequent recognition by PRRs occurs during many cellular processes, including infection, cell death and neurodegeneration, and this will be the focus of the rest of this Review.
mtDNA-dependent activation of cGAS-STING signalling mtDNA release in infection Through necessity, cells have evolved elegant systems to detect the presence of invading pathogenic DNA. Cyclic GMP-AMP synthase (cGAS) is one such direct detector, which binds dsDNA to form a dimer [23, 24] . cGAS then undergoes a conformational change which facilitates the conversion of ATP and GTP into 2 0 3 0 -cyclic GMP-AMP (cGAMP) [25] [26] [27] [28] [29] [30] [31] . cGAMP is a second messenger, which binds the endoplasmic reticulum (ER)-resident protein stimulator of interferon genes (STING) inducing a conformational change in its C-terminal tail. TANK-binding kinase 1 (TBK1) is recruited to STING which phosphorylates it and the transcription factor interferon regulatory factor 3 (IRF3), eliciting the transcription of hundreds of interferon stimulatory genes (ISGs) that are potently anti-viral [32] (Fig 2) . cGAS was assumed to be primarily cytosolic to avoid persistent activation by self-DNA in the nucleus, but recent work has shown it to be present in the nucleus [33, 34] Infection with the bacterial pathogen Mycobacterium tuberculosis triggers cGAS activation and subsequent IRF3-dependent type I interferon response [50] [51] [52] . This was assumed to be solely due to detection of mycobacterium DNA, but other studies have identified a role for mitochondrial stress and ensuing release of mtDNA into the cytoplasm [53]. This observation is strain-dependent but does propose a role for mitochondrial stress and dynamics on the M. tuberculosis-induced release of mtDNA. Previous work has observed cytochrome c release from mitochondria in cells infected with M. tuberculosis, indicating that there may be a possible role for BAX/BAK-dependent mitochondrial permeabilisation (discussed in detail later) in infection-related mtDNA release [54] (Fig 2) .
Pathogen-infected cells often secrete IL-1b due to inflammasome activation. A recent report by Aarreberg et al discovers a link between IL-1b secretion in infected cells, which can then activate a cGAS-STING-dependent type I interferon response in surrounding bystander cells. Interestingly, IL-1b stimulation of bystander cells increases mitochondrial mass, decreases mitochondrial membrane potential and induces mtDNA release [55] . However, mtDNA release is observed in the absence of detectable cytochrome c release and cell death, suggesting that this is not the mechanism of mtDNA release, although it does not rule out limited mitochondrial permeabilisation seen by us and others in the context of infection (see below). This is not the first time IL-1R signalling has been implicated in cell-intrinsic defence [56-58], but it is the first to suggest that mtDNA release plays a key role in the initiation of cGAS-STING signalling in the bystander cells.
mtDNA activation of cGAS-STING during cell death During programmed cell death, the pro-apoptotic proteins BAX and BAK permeabilise the mitochondrial outer membrane to allow the passage of pro-apoptotic molecules to move from the inner membrane space into the cytosol, where they can initiate a caspase cascade, resulting in a rapid cell death [59] . White et al and Rongvaux et al showed that in the absence of apoptotic caspase activation, mtDNA activates cGAS in a promiscuous manner, which in vivo leads to mildly elevated IFN-b protein levels in blood, though a level sufficient to induce the expression of interferon-stimulated genes [37, 38] (Fig 3) . This suggests that apoptotic caspases play a crucial role in dampening type I interferon responses in dying cells, maintaining the "immune-silent" nature of apoptosis (Fig 3) . Further work has shown that apoptotic caspases directly cleave cGAS, IRF3 and mitochondrial anti-viral signalling protein (MAVS), Various mitochondrial stresses including bacterial or viral infection can lead to mtDNA release. Alternatively, activation of BAX and BAK leads to outer mitochondrial membrane permeabilisation (MOMP) and mtDNA release. Once cytoplasmic, mtDNA can bind the DNA sensing protein cGAS that catalyses the production of the secondary messenger 2 0 3 0 cyclic GMP-AMP (2 0 3 0 cGAMP) from ATP and GTP. cGAMP binds the adaptor molecule STING on the ER leading to activation of TBK1 kinase. Active TBK1 phosphorylates the transcription factor IRF3 initiating a type I interferon response.
key proteins required for the production of type I interferon [60], supporting the notion that caspases dampen the immune response during cell death. High-resolution imaging studies have further expanded our understanding of how mtDNA is released from the mitochondria during cell death. We and others recently showed that BAX and BAK can permeabilise the mitochondrial outer membrane, but in the context of caspase inhibition these pores grow dramatically, sufficient to allow inner membrane herniation and extrusion of mtDNA [61-63] (Fig 3) . We found that under caspase-inhibited conditions, mitochondrial permeabilisation leads to down-regulation of inhibitor of apoptosis proteins (IAPs), NF-jB-inducing kinase (NIK) activation and an NF-jB transcriptional program, in addition to mtDNA release-induced cGAS-STING activation [64] . The cytokines and chemokines up-regulated via NF-jB after mitochondrial permeabilisation can serve to promote macrophage activation [64, 65] . This leads to robust anti-tumour effects, highlighting a potential therapeutic role for caspase inhibition in cancer treatment [64] . Collectively, these results help to reconcile how predominantly cytosolic cGAS can be activated by mtDNA during cell death. Nevertheless, a number of unresolved questions remain. Firstly, is inner membrane permeabilisation a regulated process, and if so, how? A rapid inner membrane permeabilisation of sufficient size to allow the passage of small ions is observed minutes after outer membrane permeabilisation [61], but is insufficient to allow mtDNA nucleoid extrusion and is probably only transient, as inner membrane potential can be maintained after outer membrane permeabilisation [66-69]. Secondly, there are cell type differences in the degree of inner membrane permeabilisation, as different studies report varying degrees of mtDNA release during cell death [61,62], implying that specific cell-intrinsic factors play a role in inner membrane permeabilisation. Finally, the physiological relevance of cell death-related mtDNA release is unknown. Most cell types undergo rapid and complete caspase-dependent apoptosis in vivo, presumably limiting any potential for mtDNA-driven inflammation during cell death. However, some cell types, for instance cardiomyocytes, display deficient caspase activity downstream of mitochondrial permeabilisation [70] . Such cells might generate a greater type I anti-viral interferon response after mitochondrial permeabilisation. Alternatively, cGAMP might transfer from apoptotic to healthy cells, serving as an "early warning" defence system, instructing healthy cells to transcribe genes important for their survival (Fig 4) [71,72]. In addition to DNA, mitochondria also possess dsRNA which is known to be potently immunogenic [73] . Mitochondrial dsRNA arises from transcription of both the heavy and lights strands of mtDNA; however, although the light strand is rapidly degraded the heavy strand is not, and nearly all the dsRNA detected in the cytoplasm are of mitochondrial origin. The mitochondrial helicase SUV3 and polynucleotide phosphorylase PNPase dampen the accumulation of dsRNA, but when these are depleted, dsRNA accumulates in the cytoplasm where it activates a type I interferon response driven by the dsRNA receptor MDA5 [74]. Silencing of BAX and BAK suppresses the type I interferon response, strongly suggesting that BAX/BAK-dependent mitochondrial outer membrane permeabilisation is responsible for mitochondrial dsRNA escape into the cytoplasm [74] Furthermore, patients with mutations leading to a decrease in PNPT1, the gene that encodes PNPase protein, exhibit greater accumulation of dsRNA and elevated interferon levels in their serum [74] .
Mitochondrial outer membrane permeabilisation is a rapid and complete event, spreading to all mitochondria in a cell. Following formation of BAX/BAK pores, pro-apoptotic proteins such as cytochrome c are released from the intermembrane space where they initiate the caspase cascade, culminating in cell death. However, we have found that under conditions of sub-lethal stress, a limited number of mitochondria in a cell can undergo permeabilisation, called minority MOMP, leading to genomic instability and Following a pro-apoptotic stress, BAX and BAK are activated leading to mitochondrial outer membrane permeabilisation. This enables the release of caspase-activating proteins from the mitochondrial intermembrane space. Following this, macropores form on the mitochondrial outer membrane causing extrusion and permeabilisation of the inner membrane. This enables release of mtDNA. Mitochondrial double-stranded RNA (dsRNA) can also be released. Collective release of these molecules triggers inflammation via MAVS, cGAS-STING and NF-jB. Caspase activity is anti-inflammatory, in part, through direct cleavage and inactivation of inflammatory signalling molecules. How else might mtDNA be released from mitochondria? Another potential mechanism for mtDNA release from mitochondria is through the mitochondrial permeability transition pore (mPTP) [77, 78] . The exact composition of the pore is unclear, although there seems to be consensus that cyclophilin D is present [79] . The mPTP spans the mitochondrial inner membrane and forms in response to high mitochondrial calcium concentration and various other cellular stresses. However, the mPTP is predicted to only allow the efflux of molecules smaller than 1.5 kDa, much smaller than a mtDNA nucleoid [80, 81] . In line with this, studies have shown that only fragments of mtDNA can pass through the mPTP [77,82,83]. It remains possible that sustained opening of the pore can lead to swelling of the mitochondria and subsequent rupture of the inner membrane, which would permit the efflux of mtDNA into the cytoplasm. The involvement of mPTP in mtDNA release during cell death has been ruled out [61], but chitosan, a vaccine adjuvant, appears to induce a cGAS-STING-and mPTP-dependent type I interferon response. This is possibly due to mtDNA release, though a direct role for mtDNA has not been rigorously assessed [84] . An intriguing recent report suggests that cells experiencing mitochondrial stress caused by the lack of mitochondrial endonuclease G release mtDNA through pores formed by oligomers of the voltagedependent anion channel (VDAC) [85] . As mitochondrial DNA release is thought to play a role in the pathogenesis of lupus [86,87], a role for VDAC pore formation was tested in an in vivo model of lupus-like disease. Using the VDAC1 oligomerisation inhibitor VBIT-4, the authors were able to reduce lupus-like symptoms in lupus-prone mice, providing a rationale to target VDAC-mediated mtDNA release in this disease [85] . [99] [100] [101] [102] . Gain-of-function mutations in STING itself lead to an up-regulation of type I interferon responses and lupus-like symptoms in patients [103, 104] . DNase II deficiency in humans leads to autoinflammation with increased type I IFN [105] and in mice causes arthritis [106] . This is thought to be due to the lack of self-DNA degradation in dead cells engulfed by macrophages resulting in sustained cGAS-STING stimulation [98, 106, 107] , and AIM2 inflammasome formation [108, 109] with a possible contribution of endosomal TLRs [108] . Myocardial infarction (MI) is another condition known to involve a strong inflammatory component. King et al [110] showed that ischaemic cell death and engulfment by macrophages drives an IRF3-dependent type I IFN response. Genetic or pharmacological disruption of cGAS-STING signalling in mice improved their outcomes post-MI, proposing this signalling axis as suitable for therapeutic intervention in patients [110, 111] . While it is not clear if this is due to mtDNA release per se, increased mtDNA in plasma from patients with heart disease has been frequently observed [112] [113] [114] . Clearly, inhibiting the cGAS-STING pathway in these disease settings might be beneficial to patients. Small molecules targeting both cGAS [115, 116] and STING [117] have been developed, with STING antagonists emerging as the most promising. Blocking the IFNAR receptor to block interferon signalling in SLE patients had seemed like a viable therapeutic route; however, late-stage clinical trials in this area have failed, prompting more investigation of how important interferon signalling is in the pathogenesis of SLE. The ability to turn immunologically "cold" tumours "hot" and make them more responsive to immunotherapy is a desirable outcome in cancer treatment. Efficient T-cell responses to tumour cells is a critical step to durable cancer treatment control [118] . STING is required for spontaneous CD8 + T-cell priming in vivo [119] . Mechanistically, dying tumour cells transfer their DNA to antigen-presenting dendritic cells when phagocytosed, eliciting cGAS-STING-IRF3 signalling leading to an anti-tumour T-cell response [119] [120] [121] . Activation of STING by addition of exogenous cGAMP can also enhance anti-tumour immunity after irradiation [120] , the first evidence that therapeutic activation of STING may improve cancer therapy. This effect was later shown to be exclusive to dendritic cells over macrophages; blockade of the "don't eat-me" signal CD47 results in increased tumour-originated mtDNA in the cytosol of DCs and is required for the cross-priming and type I IFN response mediated through cGAS [122] . Dying tumour cells transfected with exogenous cytosolic DNA, viral DNA or cyclic dinucleotides (CDNs) have a greater capacity to activate STING signalling in antigen-presenting cells, enhancing T-cell priming and expansion of anti-tumour T cells [123] . Therefore, it is also possible that mtDNA may act as a STING activator in antigen-presenting cells (APCs) under certain circumstances, for example when apoptotic caspases are inhibited. Another example of immune cell communication is in the interaction of T cells with antigen-presenting dendritic cells. Upon formation of an immunological synapse between these two cell types, T cells shed extracellular vesicles (EVs) containing genomic and mtDNA. These EVs are taken up by the dendritic cell, triggering a cGAS-STING-dependent anti-viral response, conferring resistance to subsequent viral infection [124] . In the context of cancer treatment, it is plausible that apoptotic cellcontaining dendritic cells could stimulate a similar effect in T cells, generating longer lived dendritic cells for more durable treatment responses [125] . Together, these data and many others provide a rationale for enhancing STING signalling in cancer treatment, and this is currently under active investigation [126, 127] .
mtDNA release, cGAS-STING and neurodegeneration Under normal, homeostatic conditions, damaged or stressed mitochondria are eliminated from the cell by a type of mitochondrialselective autophagy called mitophagy [128] . Mutations in proteins involved in mitophagy pathways can contribute to neurodegeneration. This is perhaps best evidenced for PINK1/Parkin-dependent mitophagy. For instance, loss-of-function mutations in the PINK1/ Parkin pathway of mitophagy associate with early onset Parkinson's disease [129] [130] [131] [132] [133] . In a simplified view, the kinase PINK1 is activated on dysfunctional mitochondria where it phosphorylates ubiquitin. Phospho-ubiquitin allosterically activates the E3 ubiquitin ligase Parkin leading to enhanced mitochondrial ubiquitination that serves as an autophagic signal to remove the damaged mitochondrion [134] [135] [136] . Parkinson's disease is associated with neuroinflammation [137] , and the serum from Parkinson's patients is often enriched for pro-inflammatory cytokines, including TNF, IL-1b, IFNɣ and IL-6 [138, 139] . However, many of the studies elucidating the mechanistic basis of Parkinson's have been performed in cultured cell lines, and despite much effort, the in vivo relevance of PINK1/ Parkin-mediated mitophagy was not well understood, particularly since mice that lack either PINK1 or Parkin exhibit no Parkinson'slike disease phenotypes [140] [141] [142] . Knowing that defective mitochondria can release innate immune-activating DAMPs, Sliter et al [143] investigated the effect of exhaustive exercise or mtDNA mutation on inflammation. When challenged with exhaustive exercise, Parkin À/À or Pink1 À/À mice displayed higher serum levels of proinflammatory IL-6 and IFN-b when compared to wild-type mice, in addition to increased levels of uncleared mitochondria. Remarkably, this could be completely rescued by deletion of STING or administering IFNAR-blocking antibody to mice, strongly suggesting that mtDNA released from damaged mitochondria that are not cleared is responsible for the inflammation observed in Parkinson's patients. Interestingly, the authors also observed increased circulating mtDNA in Parkin À/À mice following exhaustive exercise, meaning that the mtDNA is not only extruded from mitochondria but also exits the cell. Mutator mice expressing a proofreading-defective mtDNA ª 2020 The Authors EMBO reports 21: e49799 | 2020 polymerase (PolG) accumulate mutations in mtDNA, which instead of causing neurodegeneration results in dopaminergic neuron loss and defective movement. While no difference in inflammatory cytokine levels was noted between wild-type, Parkin À/À or mutator mice, Parkin À/À ;mutator mice do have higher serum cytokine levels. Again, cytokine levels and the movement disorder could be completely rescued by co-deletion of STING, reinforcing the cGAS-STING axis as the major player in Parkinson's-associated inflammation. However, further work is needed to elucidate the absolute requirement for mtDNA over nuclear DNA and the precise mechanism of how mtDNA is released from the mitochondria.
mtDNA as an inflammasome activator
Inflammasomes are multi-subunit complexes which form in response to exogenous PAMPs and DAMPs [144] . One of four receptors-absent in melanoma 2 (AIM2), NOD, LRR and Pyrin domain-containing protein 1 (NLRP1), NLRP3 or NLR family CARD domain-containing protein 4 (NLRC4), bind to the adaptor molecule ASC forming a platform for the dimerisation, autoprocessing and activation of caspase-1. Active caspase-1 can then process pro-IL-1b and pro-IL-18 into their mature form so they can be secreted (see Fig 1) . The first report of mtDNA acting as an activator of inflammasomes came in 2011 when Nakahira et al [145] reported that depletion of proteins involved in autophagy leads to an accumulation of dysfunctional, persistent mitochondria exhibiting excessive ROS. These mitochondria were more prone to extrude mtDNA into the cytoplasm upon stimulation with lipopolysaccharide (LPS) or ATP, dependent on the ability to from NLRP3 inflammasomes. Interestingly, Nakahira et al suggested that as well as acting downstream of mtDNA release, NLRP3 also acts upstream, to facilitate mPTP formation on the mitochondria allowing mtDNA release. However, as already discussed, whether mPTP is sufficient to allow mtDNA translocation from the mitochondrial matrix into the cytoplasm is debatable. Extending this work, the following year Shimada et al [146] reported that during macrophage apoptosis mtDNA is released and binds NLRP3. Notably, NLRP3 appears to have a preference for oxidised mtDNA, clarifying the observations that ROS plays a crucial role in inflammasome activation [147] . Linking these observations, deletion of the autophagy receptor p62 prevents mitophagic clearance of mitochondria damaged by NLRP3 agonists, exacerbating inflammasome formation and IL-1b secretion [148] . More recent work has pointed to newly synthesised, oxidised mtDNA as the species which binds NLRP3 [149] . Zhong et al discovered that levels of the mitochondrial deoxyribonucleotide kinase CMPK2 increase upon LPS stimulation. CMPK2 catalyses a step in the synthesis of the nucleotide cytidine triphosphate, which is rate-limiting for mtDNA synthesis. Elevated dCTP levels in turn increase mtDNA replication, which is oxidised by ROS and released into the cytoplasm where it can activate NLRP3 and stimulate IL-1b secretion. However, the role of NLRP3 as a direct sensor of DNA is contentious, as many disparate signals have been reported as the common signal for NLRP3 activation [144] . Indeed, recent work from the Chen laboratory has shown that dispersal of the trans-Golgi network following K+ efflux is the likely common trigger [150] . Supporting the notion that inflammasomes and caspase activity can act upstream of mtDNA release, there are reports that caspases cause mitochondrial damage. For example, inflammasome-activated caspase-1 has been reported to damage mitochondria and promote the release of cytochrome c, indicative of mitochondrial outer membrane permeabilisation [151] . The authors suggest that this is due to mPTP formation, although a role for BAX and BAK was not rigorously assessed in this work. Impairment of mitophagy was also implicated, as Parkin was found to be a substrate of caspase-1 in macrophages, leading to an accumulation of damaged, ROS-producing macrophages [151] . Furthermore, during infection-related ER stress, NLRP3 (but not the adaptor protein ASC or caspase-1) is involved in caspase-2 activation and cleavage of the pro-apoptotic protein BID, promoting mitochondrial permeabilisation [152] .
Neutrophil extracellular traps
So far, we have mainly discussed the cell autonomous role of mtDNA release; however, it is becoming clear that mtDNA can also be extruded from the mitochondria, into the cytoplasm and outward further into the extracellular space. One interesting example of this is in the generation of neutrophil extracellular traps, and in particular the role of mtDNA in their formation (Fig 4) .
Neutrophils are the first line of attack in infection, capable of engulfing pathogens and degranulating, the process of releasing soluble anti-microbials. In 2004, Brinkmann and colleagues discovered that upon stimulation with IL-8, phorbol myristate acetate (PMA) or LPS, neutrophils extruded vast fibrous networks, which they termed neutrophil extracellular traps (NETs) [153] . Analysis of these NETs showed that they contained a variety of microbialkilling proteins, including elastase, cathepsin G and myeloperoxidase. However, they also contain DNA, as noted by reactivity with antibodies against histones and DNA intercalating dyes. Successive work showed that NETs were also enriched for mtDNA [154] [155] [156] . NET formation has been well studied in patients with systemic lupus erythematosus (SLE), an autoimmune condition hallmarked by the appearance of autoantibodies against dsDNA and RNAprotein complexes, resulting in elevated type I interferon responses. A number of studies show that mtDNA is part of NETs formed in SLE. Caielli et al [87] found that in healthy neutrophils, mitochondria with oxidative damage are removed not via mitophagy, but by extruding their mitochondrial matrix contents, including TFAM-mtDNA nucleoids, into the extracellular space. These TFAM-mtDNA nucleoids are devoid of oxidised DNA, and so do not activate plasmacytoid dendritic cells (pDCs) and thus are not immunogenic. Healthy neutrophils remove oxidised mtDNA by signalling PKA phosphorylation of TFAM which initiates its degradation and by shuttling oxidised mtDNA into lysosomes. In contrast, neutrophils in SLE have reduced PKA activation and so do not degrade TFAM as efficiently, leading to the extrusion of immunogenic oxidised mtDNA [87] . Another report reveals ROS to be an important mediator for neutrophils to produce oxidised mtDNA-containing NETs in response to stimulation by ribonucleotide immune complexes (RNP ICs) [86] . The authors also found that injecting this DNA was pro-inflammatory and dependent on the STING pathway revealing a dual role for mitochondria in providing the source of DNA for NETs and oxidising it for maximal interferogenic response in SLE [86] (Fig 4) . Sustained IFNa signalling in SLE is also known to deregulate mitochondrial metabolism in monocytes, leading to reduced autophagy and an accumulation of mtDNA in the cytoplasm. This leads to cGAS-STING activation which promotes secretion of TNF and IL-6 and the expansion of self-DNA autoreactive lymphocytes [157] . It is now also appreciated that other cell types, including lymphocytes and eosinophils, can secrete mtDNA-containing webs which act to prime type I interferon responses in peripheral blood mononuclear cells [158, 159] .
Nuclear DNA is prepared for expulsion as NETs through a highly regulated process involving decondensation of chromatin and citrullination of histones. Furthermore, plasma membrane permeabilisation is also regulated, inevitably leading to cell death. Within minutes of stimulation, neutrophils rapidly produce NETs, whereas the death of neutrophils (dubbed "NETosis") occurs~2 h after [160] . While these two phenomena are often conflated in the literature, the timing argues against a general lytic mechanism of mtDNA release. In fact, release of mtDNA as NETs seems to be energydependent [161] . The precise mechanism of mtDNA escape during NET formation remains to be elucidated; one possibility is that it may be due to BAX/BAK pore formation on the mitochondrial outer membrane [61,62], although this seems unlikely as this would induce a rapid cell death.
mtDNA and TLR9
The Toll-like family of receptors (TLR) recognise a plethora of different bacterial features to instigate innate immunity. TLR9 recognises hypomethylated CpG motifs found in bacteria. TLR9 is expressed primarily in monocytes, macrophages, plasmocytoid dendritic cells and B lymphocytes. In resting cells, TLR9 resides on the endoplasmic reticulum, but recognition of DNA occurs in the endolysosomes (see Fig 1) [162] [163] [164] [165] . DNA-bound TLR9 recruits MyD88 which activates MAPK and NF-jB, inducing an inflammatory response. In common with bacterial DNA, mtDNA is hypomethylated at CpG motifs, making it a potent activator of TLR9 [166, 167] . mtDNA detection by TLR9 was first noted in 2010 by Zhang et al, who observed that during systemic inflammatory response syndrome (SIRS) mtDNA was released into the blood where it can activate TLR9 on neutrophils [168, 169] . In the heart, autophagy is required to remove damaged mitochondria and maintain heart function during hemodynamic stress [170] . However, when DNase II, a lysosomal DNase, is deleted from cardiac cells, the mice succumb faster following heart pressure overload [171] . Delving deeper into the mechanism, the authors found that this was due to an increase in mtDNA which has escaped degradation, thus activating a TLR9-dependent inflammatory response [171] . Mitochondrial DNA released from dying cells or as part of NETs can form a complex with the anti-microbial peptide LL-37. This mtDNA:LL-37 complex evades degradation by DNase II and can activate TLR9 on pDCs, neutrophils and endothelial cells to exacerbate atherosclerosis [172] . High-mobility group box 1 (HMGB1) is a DNA-binding protein released from necrotic [173] and cytokinestimulated cells [174] . HMBG1 binds a receptor, called RAGE, leading to inflammatory signalling. In particular, HMGB1 has been shown to be released from pDCs following stimulation with CpG oligodeoxynucleotides (ODNs). CpG-ODNs can bind and activate TLR9, but when complexed with HMGB1 the inflammatory response is augmented through HMGB1 activation of RAGE [175] . In an analogous manner, TFAM co-operates with mtDNA released from necrotic cells to increase pro-inflammatory signalling in pDCs through RAGE and TLR9 [176, 177] .
TLR9 has been particularly well studied in liver pathologies. In liver cancer, hypoxia triggers the translocation of mtDNA and HMGB1 into the cytoplasm of cancer cells to activate TLR9, resulting in tumour cell proliferation [178] . TLR9 is crucial for the development of acetaminophen-induced hepatotoxicity [179] and fibrosis [180] . Development of non-alcoholic steatohepatitis (NASH) involves innate immunity, with hepatic stellate cells and macrophage-like Kupffer cells being particularly relevant. Mice fed a choline-deficient amino acid-defined diet develop NASH, whereas TLR9 À/À mice do not, implicating TLR9 as a requirement for NASH development [181] . The precise ligand for TLR9-derived liver disease was poorly understood, although the observation that NASH patients had higher mitochondrial mass, but reduced respiration, suggested that mitochondria may play a role [182] . In line with these observations, Garcia-Martinez et al [183] found that mice and human patients with NASH exhibited higher levels of oxidised mtDNA in hepatocytes and plasma. As the oxidisation of mtDNA increases its ability to activate TLR9, the authors confirmed that was the case. Importantly, mice dosed with a TLR9 antagonist displayed reduced symptoms of NASH, validating the importance of mtDNA release and TLR9 signalling in the pathogenesis of NASH [183] . NASH is characterised by different forms of cell death, most prominently apoptosis [184] and necrosis [185, 186] . In hepatocytes, mitochondrial permeabilisation results in an increase of DNase II activity, and knockdown of DNase II switches the mode of cell death to a RIP1-dependent non-apoptotic form [187] . Importantly, this is due to the release of mtDNA after mitochondrial permeabilisation, which triggers TLR9 signalling and subsequent IFNb secretion. In mice fed a high-fat diet, a model of NASH, DNase II activity is diminished, providing a mechanistic link as to how necrosis of hepatocytes can augment NASH symptoms in patients [187] . It is unclear why the release of mtDNA triggers either cGAS-STING or TLR9 signalling in different studies; however, it may be due to different cell types, length or oxidation status of mtDNA, activity of DNA nucleases or different cellular compartments.
Mutations in OPA1, a protein required for mitochondrial inner membrane fusion and cristae formation, have been reported to cause mtDNA instability [188] [189] [190] [191] . Deletion of OPA1 in skeletal muscle, a tissue with high metabolic demands, predictably results in mitochondrial dysfunction, mtDNA stress and inflammation leading to reduced growth and early death in mice [192, 193] . Interestingly however, OPA1 deletion leads to disruption of mitophagy due to impaired autophagic flux resulting in higher levels of dysfunctional mitochondria in these tissues [194] . When mtDNA localisation was examined, following OPA1 deletion there is high co-localisation of mtDNA and TLR9, implicating TLR9 as the driver of OPA1-deletion inflammation [194] .
Transfer of mtDNA between cells
So far, this Review has mainly focussed on the cell-intrinsic biological effects of mtDNA release. However, it is possible that released mtDNA nucleoids could move from one cell to another, thus "spreading" the inflammatory signal across a population of cells. It is now well established that mitochondria, including mtDNA, can be transferred between cells (Fig 4) . A seminal study in 1989 was the first to describe such a phenomena, where cells devoid of mtDNA (q 0 cells) and thus lacking respiratory competence could be repopulated with mitochondria from other cell lines [195] . More recent work has shown that following stroke, whole mitochondria can be transferred from astrocytes to neurons, a process proven to be beneficial to recovery [196] . In cancer models, q 0 cells have delayed tumour growth, likely due to defects in energy production. Horizontal transfer of mitochondria from cells in the tumour microenvironment restored respiration in q 0 cells and instigated tumour growth [197] . Horizontal transfer of mitochondria could occur through a number of different mechanisms. Firstly, cancer cells can form tunnelling nanotubes with cells in the tumour microenvironment, through which cytoplasmic contents, including mitochondria, can be transferred [198] . Tunnelling nanotubes form between endothelial cells and cancer cells to transfer mitochondria, conferring chemoresistance to the cancer cell [199] but also between early apoptotic cells and healthy cells, where mitochondrial transfer can reverse apoptosis [200] . Secondly, mtDNA has been proposed to be packaged into extracellular vesicles (EVs). Specifically, cancer-associated fibroblasts can package entire mitochondrial genomes into EVs which then fuse with cancer cells to transfer mtDNA. Importantly, the size of these EVs,~100 nm, is far below the size of a mitochondria, so making it unlikely that an entire mitochondria is transferred in this manner [201] . However, mtDNA nucleoids are within these size constraints [21] . It is important to note that other studies see transfer of entire mitochondria between cells, and so whether these or just mtDNA genomes are transferred is controversial [202] . Thirdly, mitochondria can be directly transferred between cells through connexin 43 gap junctions, as had been seen between bone marrow-derived stromal cells and pulmonary alveoli during lung injury [203] . Interestingly, transplanting tumour or embryonic stem cells into hosts with the same nuclear DNA background but different mtDNA from allogenic mouse strains resulted in rejection [204] . Mechanistically, this is dependent on MyD88, the adaptor molecule required for TLR9 signalling, suggesting that TLR9 may be the PRR in this situation [204] . However, whether or how mtDNA is released from these cells is unknown, but it is clear that allogenic mtDNA can trigger innate immune pathways. This hints at the intriguing notion that inflammation could spread between cells via detection of mtDNA, perhaps through connexin 43 gap junctions, in a similar manner to the observation that cGAMP can transfer to activate STING in neighbouring cells [71] (Fig 4) . Contrary to this is data showing that cell-free mtDNA (for example, as seen in sepsis) can actually suppress inflammation [205] . Increased serum concentration of mtDNA is associated with a poorer outcome in sepsis patients, and injection of mtDNA in mice suppresses the adaptive immune response in a TLR9-dependent manner [205] . Immunosuppressive markers, such as an increase in PD-L1 expression in the spleen, are seen in mice injected with mtDNA, which is reflective of what is seen in sepsis patients [205] . Clearly, there is conflicting data on the immunostimulatory or immunosuppressive role of cellfree mtDNA, which may depend on pathophysiological context; nevertheless, release of mtDNA appears to potently affect the immune system.
Conclusions and future perspectives
Mitochondria are multi-faceted organelles orchestrating key events in both life and death. They represent a rich source of DAMPs which can potently trigger the innate immune system, such as ATP, formyl peptides and mtDNA. Possibly stemming from its bacterial origin, mtDNA is particularly effective at initiating inflammatory and antiviral signalling.
The last number of years has seen an explosion in interest in how mitochondria initiate innate immunity in the context of pathogen invasion, cell death and pathology. However, many of these studies leave us with unresolved questions as to precisely how mtDNA is extruded from the mitochondria. In the context of cell death, it is now clear that BAX and BAK form the pores on the mitochondrial outer membrane through which the inner membrane herniates, leading to mtDNA release, although how the inner membrane permeabilises is as yet not fully resolved [61, 62] . Many other studies have suggested that the mPTP is involved in various contexts, but again this is controversial. Clearly, further investigation is required, whether to determine a more universal role for BAX/BAK-dependent mtDNA release, utilising our current knowledge of the nature of the mPTP, or whether an altogether unknown mechanism is involved.
It is also apparent that cellular context will determine how mtDNA causes inflammation. cGAS-STING signalling seems to be widely available across most cell types, a notable exception being some transformed cells. However, TLR9 protein expression appears to be restricted to immune cells, as does expression of inflammasome components. Perhaps most interesting will be determining what the outcomes of triggering innate immunity with cytosolic or cell-free mtDNA are. For example, in the context of cell death, does production of cGAMP in apoptotic cells transfer to healthy apoptotic cells via gap junctions to promote a deathresistant state, in a manner similar to what has been observed in astrocytes [71]? Pathogen invasion stimulates a limited degree of mtDNA release by hijacking the apoptotic machinery, so it is plausible to see how this might act as a cell-intrinsic warning system, but it will be fascinating to understand how this functions in the context of a whole tissue. Furthermore, can we leverage what we have learnt about anti-viral signalling during cell death to enhance anti-cancer therapy by inhibiting caspases? Likewise, will our understanding of how mtDNA and STING function in neurodegeneration lead to novel therapeutic strategies to enhance healthy ageing [143] ? Along these lines, mitochondrial dysfunction has been shown to induce a specific form of senescence termed MiDAS (mitochondrial dysfunction-associated senescence) [206] -given the links between ageing, senescence and inflammation, it is tempting to hypothesise that mtDNA plays a role in the initiation of this phenotype.
A broad spectrum of pathologies, from cancer, to autoimmunity and ageing all have aberrant mtDNA release as a driver or contributor of disease. Future work aimed at understanding how mtDNA is involved will no doubt afford us new therapeutic avenues with which to treat patients. 
